Further mutations with a lower frequency were observed in MTOR, NRAS, TSC1, and TSC2, indicating that the genomic targeting of the mTOR pathway occurred in 23% of all chRCC [19]. Here, MTOR is linked to chromophobe renal cell carcinoma.